[Adults] {Spam? 1.35} Forbes Draws Attention to Nuvilex (NVLX), Celgene for New Pancreatic Cancer Remedies

[Biotech Penny Stock Flyer]

Nuvilex Inc. (NVLX)

Forbes Highlights Nuvilex, Celgene for New Pancreatic Cancer Remedies

 Eli Lilly's Gemzar feeling the pressure ...

Even at its low price, Eli Lilly (LLY) is still selling at about 18 times
2012 incomes, making it one of the highest expensive biotech options in the
S&P 500, while the entity has serious downside risk if its pipeline doesn't
reap some authorizations fast . Shares are up a moderate 2% so far this
year. Worse yet for Lilly, Celgene and Nuvilex, Inc. (NVLX) have produced
data that displays their new treatments outperform Lilly's multi-billion
dollar drug Gemzar (gemcitabine) in patients with advanced, inoperable
pancreatic cancer.

Celgene shares have sustained their strong growth to near $160 per share
after the FDA in September sanctioned Abraxane (a nanoparticle
protein-bound formulation of Bristol-Myers Squibb's Taxol) together with
gemcitabine for pancreatic cancer patients. The cocktail presented a 59%
improvement in gemcitabine's one-year survival rate and a average total
survival of 8.5 months aast 6.7 months for gemcitabine alone, though it
passed with it a rise in treatment-related side effects.

Forbes just highlighted Celgene's successes, while actually spending more
time focusing on Nuvilex and their living cell encapsulation technology and
their use for the treatment of pancreatic cancer. Nuvilex's treatment
brings together the use of encapsulated cells that are adept in changing
the cancer prodrug ifosfamide into its cancer-killing form combined with
the prodrug itself. In a mid-stage clinical trial, Nuvilex's treatment was
shown to outstrip anything that Abraxane plus gemcitabine or Gemzar itself
had to offer. In that Phase 2 trial using Nuvilex's therapy, the average
survival time was about two times that observed with Gemzar (11 months vs.
5.4 months) compared to historical information on Gemzar, as was the
one-year survival period (36% vs 18%). Just as impressive, because of the
use of Nuvilex's therapy in which the Ifosfamide dosing level was reduced
by two-thirds from that typically used for cancer treatment, the
unfavorable events usually observed with ifosfamide chemotherapy were
greatly minimized.

The rubber is getting ready to meet the road for Nuvilex as it is preparing
for a large-scale Phase 3 trial positioning its technology head to head
against Gemzar, with the organization and stakeholders confident that
outcomes will enrich anything the market at this time has to offer. As was
the case in the Phase 2 trial, live cells communicating high levels of the
enzyme CYP 2B1 that activates ifosfamide will be encapsulated and implanted
alongside inoperable pancreatic tumors, followed by a low-dose regimen of
Ifosfamide.

Nuvilex has agreements with Fisher Biosciences, a division of Thermo Fisher
Scientific (TMO) for the long-term storage of the ifosfamide-activating
cells and Inno Biologics to produce clones of those cells in preparation
for the manufacture of the large count of such cells that will be necessary
for the trials. This puts Nuvilex in the company of world-class and GMP
(Good Manufacturing Practices)-compliant companies in its efforts, a fact
limited small organizations can lay claim to.

Abraxane's authorization has added at least $4B to the market
capitalization of Celgene, although the amount is possibly more as
investors priced-in the approval prior to it coming. Think about that
comparatively to the $77M market capitalization that Nuvilex at this time
commands and it's not difficult to understand why venerable financial
publications and investors are latching on to the upside potential of
Nuvilex and what sort of industry influencer it may be in the near future.

1800 Pembrook Dr., STE 300, Orlando, Fla 32810 United States



The use of research materials circulated by the auth.or is done at your own
risk. You are encouraged to do your own research before making any
investment decision in regards to the secu rity discussed herein. The
author has not been rewarded by any entity in connection with the
distribution of these materials. You should presume that as of the date of
this report or letter, the author, possibly along with or through our
owners, affiliates, employees and/or consultants, (cooperatively referred
to as the author) has a position in all company shares (and/or options of
the shares) covered herein that is consistent with the position set forth
in our report. In connection with NVLX, the author has taken a long
position. Following the disbursement of any report or letter, the author
intends to continue engaging in trnsactns in the secu rity covered herein,
and we may be long, short, and/or neutral at any time hereafter regardless
of our initial position and we preserve the right to procure or trade all
or part of our position at any time without notice. This practice could end
in our trading securities at any time before, during, and/or after the
disbursement of this report.


Unsubscribe me from this mailing
http://p1.svmcleaningrestoration.com/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=5496


-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://www.polarhome.com/pipermail/adults/attachments/20131021/04fcc7ae/attachment.html>